Aminoglycosides for life-threatening infections: A plea for an individualized approach using intensive therapeutic drug monitoring

Minerva Anestesiologica

Volumn 80, Issue 10, 2014, Pages 1135-1142

  De Waele, J J ^a   De Neve, N ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b OLV HOSPITAL   (Belgium)

Author keywords

Aminoglycoside; Pharmacokinetics; Septic; Shock

Indexed keywords

AMINOGLYCOSIDE DERIVATIVE; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

APPARENT LIFE THREATENING EVENT; ARTICLE; CONTINUOUS RENAL REPLACEMENT THERAPY; CREATININE CLEARANCE; CRITICAL ILLNESS; CRITICALLY ILL PATIENT; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG USE; ENDOCARDITIS; GONORRHEA; HEMODIALYSIS; HUMAN; INFECTION; INTENSIVE CARE; INTENSIVE CARE UNIT; KIDNEY CLEARANCE; LIFE THREATENING INFECTION; MEDICAL DECISION MAKING; NEPHROTOXICITY; NEUROMUSCULAR BLOCKING; OTOTOXICITY; PHARMACODYNAMICS; PLAGUE; TREATMENT INDICATION; TUBERCULOSIS; TULAREMIA; VOLUME OF DISTRIBUTION; BACTERIAL INFECTIONS; PERSONALIZED MEDICINE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CRITICAL ILLNESS; DRUG MONITORING; HUMANS; PRECISION MEDICINE;

EID: 84925451299     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Hanberger H, Edlund C, Furebring M, G Giske C, Melhus A, Nilsson LE et al. Rational use of aminoglycosides-review and recommendations by the Swedish Reference Group for Antibiotics (SRGA). Scand J Infect Dis 2013;45:161-75.
2. Yamashita Y, Takada T, Kawarada Y, Nimura Y, Hirota M, Miura F et al. Surgical treatment of patients with acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007;14:91-7.
3. Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs 2011;71:2277-94.
4. Craig WA. Optimizing Aminoglycoside Use. Critical Care Clinics 2011;27:107-21.
5. Baddour LM, Wilson WR, Bayer AS, Fowler VGJ, Bolger AF, Levison ME et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005;111:e394-e434.
6. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116:1736-54.
7. Delannoy PY, Boussekey N, Devos P, Alfandari S, Turbelin C, Chiche A et al. Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias. Eur J Clin Microbiol Infect Dis 2012;31:2293-9.
8. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012;25:450-0.
9. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004;328:668.
10. Marcus R, Paul M, Elphick H, Leibovici L. Clinical implications of beta-lactam-aminoglycoside synergism: systematic review of randomised trials. Int J Antimicrob Agents 2011;37:491-503.
11. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005;41:149-158.
12. Taccone FS, Donadello K. Is two (antibiotics) better than one? Minerva Anestesiol 2013;79:1300-5.
13. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med 2010;38:1773-85.
14. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet 1999;36:89-98.
15. Rougier F, Claude D, Maurin M, Sedoglavic A, Ducher M, Corvaisier S et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. Antimicrob Agents Chemother 2003;47:1010-6.
16. Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med 2008;36:S146-S151.
17. Taccone FS. Optimising amikacin regimens in septic patients. Int J Antimicrob Agents 2012;39:264-5.
18. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.
19. Goncalves-Pereira J, Martins A, Povoa P. Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. Clin Microbiol Infect 2010;16:1258-63.
20. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008;30:674-81.
21. Peris-Marti JF, Borras-Blasco J, Rosique-Robles JD, Gonzalez-Delgado M. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation. J Clin Pharm Ther 2004;29:65-70.
22. Barletta JF, Johnson SB, Nix DE, Nix LC, Erstad BL. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma 2000;49:869-72.
23. Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur Rev Med Pharmacol Sci 2013;17:285-91.
24. Delattre IK, Musuamba FT, Nyberg J, Taccone FS, Laterre PF, Verbeeck RK et al. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit 2010;32:749-56.
25. Mann HJ, Fuhs DW, Awang R, Ndemo FA, Cerra FB. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm. 1987;6:148-53.
26. Galvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E et al. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011;38:146-51.
27. Bartal C, Danon A, Schlaeffer F, Reisenberg K, Alkan M, Smoliakov R et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med 2003;114:194-8.
28. Udy AA, Roberts JA, De Waele JJ, Paterson DL, Lipman J. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012;39:455-7.
29. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete AG, Hoste E et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 2013;17:R84.
30. D'Arcy DM, Casey E, Gowing CM, Donnelly MB, Corrigan OI. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol 2012;13:14.
31. Taccone FS, de Backer D, Laterre PF, Spapen H, Dugernier T, Delattre I et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011;37:531-5.
32. Roberts JA, Field J, Visser A, Whitbread R, Tallot M, Lipman J et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 2010;54:3635-40.
33. Taccone FS, Laterre PF, Spapen H, Dugernier T, Delattre I, Layeux B et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010;14:R53.
34. Cox ZL, Nelsen CL, Waitman LR, McCoy JA, Peterson JF. Effects of clinical decision support on initial dosing and monitoring of tobramycin and amikacin. Am J Health Syst Pharm 2011;68:624-32.